LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="De Leo, Pasqualina"
  2. AU="Chatterjee, Pabitra B"
  3. AU="Papandreou, Z"
  4. AU="Moore, E F"
  5. AU="Verhoeven, V"
  6. AU="Benchat, Noureddine" AU="Benchat, Noureddine"
  7. AU="El-Rayes, Mahmoud Kamil"
  8. AU="Aude de Watteville"
  9. AU="Balm, P W"
  10. AU="Peng, Zhenling"
  11. AU="Du, Peilin"
  12. AU="Yeh, Pamela"
  13. AU="Moloney, Gail"
  14. AU="Murphy, Ross G"
  15. AU="Petronilho, Sara"
  16. AU="Ordóñez, Raquel"
  17. AU="Mulvaney, Robert"
  18. AU="Amarin, Z"
  19. AU="Vadlin, S"
  20. AU="Erin E. Michalak"
  21. AU="Cassidy, Caitlin A"
  22. AU="Veronica Davalos"
  23. AU="Koba, Wade R"
  24. AU="Cui, Hongyan"
  25. AU="Ross, Nina E"
  26. AU="Atwa, Hanaa A"
  27. AU="Reid, Carly"

Suchergebnis

Treffer 1 - 10 von insgesamt 20

Suchoptionen

  1. Artikel ; Online: Treatment of immune-mediated thrombotic thrombocytopenic purpura without plasma exchange.

    Capecchi, Marco / Gazzola, Giada / Agosti, Pasquale / De Leo, Pasqualina / Mancini, Ilaria / Ferrari, Barbara / Giannotta, Juri Alessandro / Artoni, Andrea / Peyvandi, Flora

    Haematologica

    2024  

    Abstract: Not available. ...

    Abstract Not available.
    Sprache Englisch
    Erscheinungsdatum 2024-02-22
    Erscheinungsland Italy
    Dokumenttyp Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2023.284438
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.76: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: CXCR5-CXCL13 axis markers in full-term and preterm human neonates in the first weeks of life.

    Pietrasanta, Carlo / De Leo, Pasqualina / Jofra, Tatiana / Ronchi, Andrea / Pugni, Lorenza / Mosca, Fabio / Aiuti, Alessandro / Cicalese, Maria Pia / Fousteri, Georgia

    European journal of immunology

    2021  Band 51, Heft 5, Seite(n) 1289–1292

    Abstract: Term and preterm neonates have very few circulating Tfh-like cells (cTfh), and no circulating Tfr-like cells. Neonatal cTfh are ... ...

    Abstract Term and preterm neonates have very few circulating Tfh-like cells (cTfh), and no circulating Tfr-like cells. Neonatal cTfh are CXCR5
    Mesh-Begriff(e) Biomarkers ; Chemokine CXCL13/metabolism ; Disease Susceptibility ; Humans ; Immunophenotyping ; Infant, Newborn ; Premature Birth/metabolism ; Receptors, CXCR5/metabolism ; T-Lymphocytes, Helper-Inducer/immunology ; T-Lymphocytes, Helper-Inducer/metabolism ; Term Birth/metabolism
    Chemische Substanzen Biomarkers ; CXCL13 protein, human ; CXCR5 protein, human ; Chemokine CXCL13 ; Receptors, CXCR5
    Sprache Englisch
    Erscheinungsdatum 2021-02-09
    Erscheinungsland Germany
    Dokumenttyp Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202048831
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 489: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 85: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry.

    Agosti, Pasquale / De Leo, Pasqualina / Capecchi, Marco / Ferrari, Barbara / Mancini, Ilaria / Gattillo, Salvatore / Trisolini, Silvia Maria / Rinaldi, Erminia / Podda, Gian Marco / Prezioso, Lucia / Salutari, Prassede / Facchini, Luca / Caramazza, Domenica / Tolomelli, Giulia / Artoni, Andrea / Peyvandi, Flora

    Research and practice in thrombosis and haemostasis

    2023  Band 7, Heft 6, Seite(n) 102185

    Abstract: Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an acute immune TTP episode.•Caplacizumab was effective in treating acute TTP in the Italian real- ...

    Abstract •Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an acute immune TTP episode.•Caplacizumab was effective in treating acute TTP in the Italian real-world clinical setting.•Two major bleeds leading to drug discontinuation were observed.
    Sprache Englisch
    Erscheinungsdatum 2023-08-26
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2475-0379
    ISSN (online) 2475-0379
    DOI 10.1016/j.rpth.2023.102185
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel ; Online: Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.

    Capecchi, Marco / De Leo, Pasqualina / Abbattista, Maria / Mancini, Ilaria / Agosti, Pasquale / Biganzoli, Marina / Suffritti, Chiara / Ferrari, Barbara / Lecchi, Anna / La Marca, Silvia / Padovan, Lidia / Scalambrino, Erica / Clerici, Marigrazia / Tripodi, Armando / Artoni, Andrea / Gualtierotti, Roberta / Peyvandi, Flora

    Haematologica

    2023  Band 108, Heft 11, Seite(n) 3152–3155

    Mesh-Begriff(e) Humans ; COVID-19 Vaccines/adverse effects ; Purpura, Thrombotic Thrombocytopenic/therapy ; COVID-19/prevention & control ; SARS-CoV-2 ; Recurrence ; Purpura, Thrombocytopenic, Idiopathic ; ADAMTS13 Protein
    Chemische Substanzen COVID-19 Vaccines ; ADAMTS13 Protein (EC 3.4.24.87)
    Sprache Englisch
    Erscheinungsdatum 2023-11-01
    Erscheinungsland Italy
    Dokumenttyp Letter
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.282478
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.76: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura.

    Bichard, Christian / Mancini, Ilaria / Agosti, Pasquale / Capecchi, Marco / De Leo, Pasqualina / Arcudi, Sara / Ferrari, Barbara / Trisolini, Silvia Maria / Longu, Francesco / Fozza, Claudio / Artoni, Andrea / Peyvandi, Flora

    Blood advances

    2022  Band 6, Heft 18, Seite(n) 5463–5466

    Mesh-Begriff(e) ADAM Proteins ; ADAMTS13 Protein ; Azathioprine/adverse effects ; Humans ; Purpura, Thrombotic Thrombocytopenic/drug therapy
    Chemische Substanzen ADAM Proteins (EC 3.4.24.-) ; ADAMTS13 Protein (EC 3.4.24.87) ; Azathioprine (MRK240IY2L)
    Sprache Englisch
    Erscheinungsdatum 2022-06-27
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022007632
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 7153: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: A Prevalent CXCR3

    Ottaviano, Giorgio / Gerosa, Jolanda / Santini, Micaela / De Leo, Pasqualina / Vecchione, Andrea / Jofra, Tatiana / Trimarchi, Cristiana / De Pellegrin, Maurizio / Agosti, Massimo / Aiuti, Alessandro / Marinoni, Maddalena / Cicalese, Maria Pia / Fousteri, Georgia

    Journal of clinical immunology

    2020  Band 40, Heft 3, Seite(n) 447–455

    Abstract: Patients with Down syndrome (DS) are characterized by increased susceptibility to autoimmunity and respiratory tract infections that are suggestive of humoral immunity impairment. Here, we sought to determine the follicular helper (Tfh) and follicular ... ...

    Abstract Patients with Down syndrome (DS) are characterized by increased susceptibility to autoimmunity and respiratory tract infections that are suggestive of humoral immunity impairment. Here, we sought to determine the follicular helper (Tfh) and follicular regulatory (Tfr) T cell profile in the blood of children with DS. Blood was collected from 24 children with DS, nine of which had autoimmune diseases. Children with DS showed skewed Tfh differentiation towards the CXCR3
    Mesh-Begriff(e) Adolescent ; Autoimmune Diseases/immunology ; Blood Circulation ; Cell Differentiation ; Cells, Cultured ; Child ; Down Syndrome/immunology ; Female ; Germinal Center/immunology ; Humans ; Immunity, Humoral ; Male ; Phenotype ; Receptors, CXCR3/metabolism ; T-Lymphocyte Subsets/immunology ; T-Lymphocytes, Helper-Inducer/immunology ; Th1-Th2 Balance
    Chemische Substanzen CXCR3 protein, human ; Receptors, CXCR3
    Sprache Englisch
    Erscheinungsdatum 2020-01-28
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 779361-3
    ISSN 1573-2592 ; 0271-9142
    ISSN (online) 1573-2592
    ISSN 0271-9142
    DOI 10.1007/s10875-020-00755-0
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1640: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: NFKB2 regulates human Tfh and Tfr pool formation and germinal center potential.

    De Leo, Pasqualina / Gazzurelli, Luisa / Baronio, Manuela / Montin, Davide / Di Cesare, Silvia / Giancotta, Carmen / Licciardi, Francesco / Cancrini, Caterina / Aiuti, Alessandro / Plebani, Alessandro / Cicalese, Maria Pia / Lougaris, Vassilios / Fousteri, Georgia

    Clinical immunology (Orlando, Fla.)

    2019  Band 210, Seite(n) 108309

    Abstract: Mutations affecting the non-canonical pathway of NF-κB were recently identified to underlie a form of common variable immunodeficiency strongly associated with autoimmunity. Although intrinsic B-cell abnormalities explain most of the humoral defects of ... ...

    Abstract Mutations affecting the non-canonical pathway of NF-κB were recently identified to underlie a form of common variable immunodeficiency strongly associated with autoimmunity. Although intrinsic B-cell abnormalities explain most of the humoral defects of this disease, detailed data on the impact of NFKB2 on follicular helper (Tfh) and regulatory (Tregs) T cells are scarce. Here, we show that Tfh, CXCR5
    Mesh-Begriff(e) Adolescent ; Adult ; Autoimmunity ; Cell Differentiation ; Cell Proliferation ; Cells, Cultured ; Child ; Common Variable Immunodeficiency/genetics ; Common Variable Immunodeficiency/immunology ; Cytokines/metabolism ; Female ; Germinal Center/immunology ; Humans ; Male ; NF-kappa B/genetics ; NF-kappa B/metabolism ; NF-kappa B p52 Subunit/genetics ; Sequence Deletion/genetics ; Signal Transduction ; T-Lymphocytes, Helper-Inducer/immunology ; T-Lymphocytes, Regulatory/immunology ; Young Adult
    Chemische Substanzen Cytokines ; NF-kappa B ; NF-kappa B p52 Subunit ; NFKB2 protein, human
    Sprache Englisch
    Erscheinungsdatum 2019-11-18
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1459903-x
    ISSN 1521-7035 ; 1521-6616
    ISSN (online) 1521-7035
    ISSN 1521-6616
    DOI 10.1016/j.clim.2019.108309
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 880: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.

    Quaranta, Maria Giovanna / Ferrigno, Luigina / Tata, Xhimi / D'Angelo, Franca / Coppola, Carmine / Ciancio, Alessia / Bruno, Serena Rita / Loi, Martina / Giorgini, Alessia / Margotti, Marzia / Cossiga, Valentina / Brancaccio, Giuseppina / Dallio, Marcello / De Siena, Martina / Cannizzaro, Marco / Cavalletto, Luisa / Massari, Marco / Mazzitelli, Maria / De Leo, Pasqualina /
    Laccabue, Diletta / Baiocchi, Leonardo / Kondili, Loreta A

    BMC infectious diseases

    2021  Band 21, Heft 1, Seite(n) 413

    Abstract: Background: The development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment of HCV, including its treatment in patients with HIV coinfection. The aim of this study was to compare the changes in liver function between ... ...

    Abstract Background: The development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment of HCV, including its treatment in patients with HIV coinfection. The aim of this study was to compare the changes in liver function between coinfected and monoinfected patients with cirrhosis who achieved HCV eradication by DAA.
    Methods: Patients with pre-treatment diagnosis of HCV liver cirrhosis, consecutively enrolled in the multicenter PITER cohort, who achieved a sustained virological response 12 weeks after treatment cessation (SVR12) were analysed. Changes in Child-Pugh (C-P) class and the occurrence of a decompensating event was prospectively evaluated after the end of DAA treatment. Cox regression analysis was used to evaluate factors independently associated with changes in liver function following viral eradication.
    Results: We evaluated 1350 patients, of whom 1242 HCV monoinfected (median follow-up 24.7, range 6.8-47.5 months after viral eradication) and 108 (8%) HCV/HIV coinfected (median follow-up 27.1, range 6.0-44.6). After adjusting for age, sex, HCV-genotype, HBsAg positivity and alcohol use, HIV was independently associated with a more advanced liver disease before treatment (C-P class B/C vs A) (OR: 3.73, 95% CI:2.00-6.98). Following HCV eradication, C-P class improved in 17/20 (85%) coinfected patients (from B to A and from C to B) and in 53/82 (64.6%) monoinfected patients (from B to A) (p = 0.08). C-P class worsened in 3/56 coinfected (5.3%) (from A to B) and in 84/1024 (8.2%) monoinfected patients (p = 0.45) (from A to B or C and from B to C). Baseline factors independently associated with C-P class worsening were male sex (HR = 2.00; 95% CI = 1.18-3.36), platelet count < 100,000/μl (HR = 1.75; 95% CI 1.08-2.85) and increased INR (HR = 2.41; 95% CI 1.51-3.84). Following viral eradication, in 7 of 15 coinfected (46.6%) and in 61 of 133 (45.8%) monoinfected patients with previous history of decompensation, a new decompensating event occurred. A first decompensating event was recorded in 4 of 93 (4.3%) coinfected and in 53 of 1109 (4.8%) monoinfected patients (p = 0.83).
    Conclusions: Improvement of liver function was observed following HCV eradication in the majority of patients with cirrhosis; however viral eradication did not always mean cure of liver disease in both monoinfected and coinfected patients with advanced liver disease.
    Mesh-Begriff(e) Aged ; Antiviral Agents/therapeutic use ; Coinfection/drug therapy ; Female ; HIV Infections/drug therapy ; Hepacivirus/genetics ; Hepatitis C/complications ; Hepatitis C/drug therapy ; Hepatitis C/virology ; Humans ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/virology ; Liver Function Tests ; Male ; Middle Aged ; Prospective Studies ; Sustained Virologic Response ; Treatment Outcome
    Chemische Substanzen Antiviral Agents
    Sprache Englisch
    Erscheinungsdatum 2021-05-04
    Erscheinungsland England
    Dokumenttyp Clinical Trial ; Journal Article ; Multicenter Study
    ISSN 1471-2334
    ISSN (online) 1471-2334
    DOI 10.1186/s12879-021-06053-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  9. Artikel: Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia.

    Toscanini, Federica / De Leo, Pasqualina / Calcagno, Giuseppe / Malfatti, Federica / Grasso, Alessandro / Anselmo, Marco

    Case reports in hepatology

    2011  Band 2011, Seite(n) 258791

    Abstract: Hepatitis B virus (HBV) reactivation is an increasingly recognized cause of morbidity and mortality in patients undergoing chemotherapy. In haematology, the risk of reactivation of B hepatitis among HBsAg-positive patients has been documented; therefore, ...

    Abstract Hepatitis B virus (HBV) reactivation is an increasingly recognized cause of morbidity and mortality in patients undergoing chemotherapy. In haematology, the risk of reactivation of B hepatitis among HBsAg-positive patients has been documented; therefore, use of lamivudine prophylaxis is recommended before starting chemotherapy. Differently, for HBsAg-negative patients with markers of previous HBV infection (i.e., presence of isolated anti-HBc positivity) (anticore patients) management strategies are not univocal. We describe a rare case of HBV reactivation in an anticore patient after fludarabine therapy for chronic lymphocytic leukaemia. The patient fully recovered after a 6-month course of lamivudine with persistent HBV-DNA clearance and loss of HBsAg. The most important feature of this case is that fludarabine alone infrequently determines HBV reactivation, especially in anticore patients. Therefore, we suggest that patients candidates to receive fludarabine therapy should be considered for lamivudine prophylaxis, not only if HBsAg-positive, but even if anticore-positive only.
    Sprache Englisch
    Erscheinungsdatum 2011-06-15
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2090-6587
    ISSN 2090-6587
    DOI 10.1155/2011/258791
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  10. Artikel: Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.

    Cenderello, Giovanni / Fanizza, Caterina / Marenco, Simona / Nicolini, Laura Ambra / Artioli, Stefania / Baldissarro, Isabella / Dentone, Chiara / De Leo, Pasqualina / Di Biagio, Antonio

    ClinicoEconomics and outcomes research : CEOR

    2017  Band 9, Seite(n) 281–293

    Abstract: Aims: Despite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian ... ...

    Abstract Aims: Despite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy).
    Methods: A retrospective analysis of the cost per care sustained for DAA treatment, relating to the period from January 1 to December 31, 2015 in five centers in Liguria was performed. All patients undergoing DAA-based treatments for hepatitis C virus (HCV) infection were enrolled. On-treatment costs included: HCV treatment, laboratory test, outpatient services, attended visits, drugs used for the management of adverse events (erythropoietin, albumin or red blood cell packs) and inpatient service admissions.
    Results: In total, 327 patients were enrolled. No difference in terms of sustained virologic response (SVR) rate among different treatments was reported. The majority (85.0%) of patients did not report any side effects and only 15 (4.6%) required hospital admission. Forty-two patients (12.8%) required high-cost drugs for the management of adverse events. The overall cost sustained was €14,744,433. DAA±ribavirin (RBV) accounted for the wide majority of this cost (98.9%; €14,585,123). Genotype (GT) 1, the most commonly treated GT, was associated with an average cost of €43,445 per patient. Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir±RBV with an average cost of €24,978 (RBV+) and €25,448 (RBV-) per patient was the most cost-effective. The average cost per SVR was €48,184. Once again, the ritonavir boosted paritaprevir/ombitasvir + dasabuvir regimen was associated with the lowest cost/SVR (€25,448/SVR [GT 1b] and similar results for other GTs).
    Conclusion: Antiviral regimen is the major contributor to costs in the treatment of HCV infection. Appropriate regimen selection could result in a major cost saving, which can be reinvested to allow more patients to be treated.
    Sprache Englisch
    Erscheinungsdatum 2017-05-22
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article
    ZDB-ID 2520698-9
    ISSN 1178-6981
    ISSN 1178-6981
    DOI 10.2147/CEOR.S129859
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang